Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.

@article{Pusceddu2016MetforminWE,
  title={Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.},
  author={Sara Pusceddu and Roberto Buzzoni and Claudio Vernieri and Laura Concas and Sara Marceglia and Luca Giacomelli and Massimo Milione and Livia Leuzzi and Daniela Femia and Barbara Formisano and Vincenzo Mazzaferro and Filippo de Braud},
  journal={Future oncology},
  year={2016},
  volume={12 10},
  pages={
          1251-60
        }
}
A bidirectional relationship seems to exist between diabetes mellitus and development of pancreatic tumors. Metformin, the most widely used drug in the treatment of Type 2 diabetes mellitus, has recently emerged as a potentially active agent in cancer chemoprevention and treatment. In this article, we discuss the potential correlation between glycemic status, administration of antiglycemic treatments, such as metformin or insulin, and prognosis of pancreatic neuroendocrine tumors patients… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…